Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

<i>Purpose</i>: The aim of this study was to evaluate the effect of switching treatment in eyes with neovascular age-related macular degeneration (nAMD) and treatment intervals of ≤6 weeks to brolucizumab. <i>Methods</i>: In this prospective series, eyes with persisting retin...

Full description

Bibliographic Details
Main Authors: Christof Haensli, Isabel B. Pfister, Justus G. Garweg
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Clinical Medicine
Subjects:
brolucizumab
ranibizumab
aflibercept
anti-VEGF
neovascular age-related macular degeneration
visual acuity
Online Access:https://www.mdpi.com/2077-0383/10/12/2666

Internet

https://www.mdpi.com/2077-0383/10/12/2666

Similar Items